• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 12th April 2016

Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.

The blog provides links to slide sets for presentations relating to going ‘beyond QALYs’ when valuing health care interventions, managed entry agreements within the UK pharmaceutical landscape, new business models for antibiotics, and economics of the market for medicines Beyond…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The blog provides links to slide sets for presentations relating to going ‘beyond QALYs’ when valuing health care interventions, managed entry agreements within the UK pharmaceutical landscape, new business models for antibiotics, and economics of the market for medicines

Beyond QALYs: A Quantum Leap Forward or a Leap in the Dark?

OHE’s Paula Lorgelly took part in the Future of Value: Insights from the Experts panel discussion, Indianapolis, on 1 March 2016.

Paula presented a paper which discusses issues with going ‘beyond quality adjusted life years (QALYs)’ when valuing health care interventions.  There are three dimensions to consider when going beyond QALYs: develop a better measure of health (e.g. one that could be condition-specific); use broader measures of benefit; consider a societal perspective (e.g. include productivity loss and carers’ effects).

Paula’s presentation focused on utilising a broader measure of benefit, focusing on alternative such as the capability approach and subjective wellbeing measures.

The panel was sponsored by Eli Lilly.

Presentation by Paula Lorgelly – Beyond QALYs: A Quantum Leap Forward or a Leap in the Dark? from Office of Health Economics

For more information contact Paula Lorgelly at OHE.

New managed entry agreements for pharmaceuticals in the UK

OHE’s Jorge Mestre-Ferrandiz presented a guest lecture on 11 March 2016 at the Max Weber Institute and Universidad Castilla-La Mancha, Spain.

Jorge presented on the current global challenges faced by the pharmaceutical industry and gave a detailed description of the current UK landscape for pharmaceuticals, including discussion of the role played by managed entry agreements.

Note that the slides are in Spanish.

New managed entry agreements for pharmaceuticals in the UK? Presentation 11 March 2016 Jorge Mestre-Ferrandiz from Office of Health Economics

For more information contact Jorge Mestre-Ferrandiz.

New Business Models for Antibiotics: Where Are We Now?

Speaking at the Superbugs & Superdrugs conference in London on 16 March 2016, OHE’s Jorge Mestre-Ferrandiz delivered a presentation on financial and collaborative incentives to accelerate clinical success for antibiotics.

Jorge discussed the economic challenges around antibiotics, and whether there is a need for a new business model. He reviewed of the impact of previous incentives, explaining what has worked in the past, and discussed possible new business models.

Presentation – New Business Models for Antibiotics: Where Are We Now? 16 March 2016 Jorge Mestre-Ferrandiz from Office of Health Economics

For more information contact Jorge Mestre-Ferrandiz.

The Economics of the Market for Medicines

Jorge Mestre-Ferrandiz also presented a guest lecture at City University, London, on 17 March 2016, on the topic of the economics of the market for medicines.

The first half of the lecture included an overview of the global challenges facing medicines manufacturers, discussion of the ‘supply side’ (focusing on research and development of new drugs), and evidence relating to the ‘demand side’ which suggests that UK spending on medicines as a percentage of GDP is already amongst the lowest in developed countries.

The second half of the lecture looked at NICE and the ‘hurdle’ of demonstrating cost-effectiveness, as well as an overview of pricing regulation, and specific characteristics of the UK market.

Presentation – The Economics of the Market for Medicines, Jorge Mestre-Ferrandiz 17 March 2016 from Office of Health Economics

For more information contact Jorge Mestre-Ferrandiz at OHE.

  • Drug Development/R&D
  • Presentations

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
Danzon_Patricia_1305 (1)
  • News
  • June 2020

Victor R. Fuchs Award for 2020 Goes to Patricia Danzon

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!